Poster
31
(#31) Real-World Sleep Medication Treatment Patterns for Patients with Bipolar I Disorder, Schizophrenia, or Major Depressive Disorder Before and After Cariprazine Initiation
Psych Congress 2025
Abstract: Introduction:Sleep disturbances occur in psychiatric diseases, and are associated with poor outcomes.However, sleep medication may increase drug-drug interactions, adverse events, non-adherence, and economic burden.Cariprazine is FDA approved to treat schizophrenia(SCZ), manic/mixed and depressive episodes of bipolar I disorder(BP-I), and as adjunct therapy for major depressive disorder(MDD).This real-world, claims-based study examined sleep medication patterns pre/post cariprazine initiation in patients with BP-I, SCZ, or MDD.
Methods:Claims data from Optum's Market Clarity database identified adults (≥19yrs) with BP-I, SCZ, or MDD who initiated cariprazine October 2015May 2022.Sleep medication fills were assessed during the baseline (1yr before index; index=first cariprazine fill) and follow-up periods (from index to study end, insurance enrollment end, cariprazine runout, or death).Outcomes included sleep medication use (baseline and follow-up) and the rates (per 100 person-years) of initiation and discontinuation during follow-up.
Results:67,236 patients (BP-I=50,728; SCZ=4,388; MDD=12,120) were included.The mean follow-up was 4.7(4.1) months.At baseline, 13.2% used sleep medication. MDD cohort had the highest sleep medication use(15.0%), followed by BP-I(13.1%) and SCZ(9.4%).Among those using sleep medication at baseline, overall discontinuation rate during follow-up was 50.2 per 100 person-years (BP-I=51.0;SCZ=45.7;MDD=48.2).During follow-up, the initiation rate for sleep medication among patients not previously using sleep medication was 10.7 per 100 person-years (BP-I=11.3;SCZ=8.1;MDD=9.2).Among patients who began using sleep medication during follow-up, the overall discontinuation rate was 124.2 per 100 person-years (BP-I=119.5;SCZ=128.3;MDD=152.6).The sleep medication use was numerically lower during follow-up(11.0%) and consistent across all indications (BP=11.2%;SCZ=7.8%;MDD=11.7%).
Conclusions:This real-world, claims-based study in patients with BP-I, SCZ, or MDD found lower sleep medication use after cariprazine initiation.
Short Description: This real-world, claims-based analysis of sleep medication treatment patterns in patients with bipolar I disorder, schizophrenia, or major depressive disorder, showed that the prevalence of sleep medication use was lower after versus before cariprazine treatment. The sleep medication discontinuation rate per 100 person-years was higher than the initiation rate per 100 person-years after versus before cariprazine treatment.
Name of Sponsoring Organization(s): AbbVie, Inc.
Methods:Claims data from Optum's Market Clarity database identified adults (≥19yrs) with BP-I, SCZ, or MDD who initiated cariprazine October 2015May 2022.Sleep medication fills were assessed during the baseline (1yr before index; index=first cariprazine fill) and follow-up periods (from index to study end, insurance enrollment end, cariprazine runout, or death).Outcomes included sleep medication use (baseline and follow-up) and the rates (per 100 person-years) of initiation and discontinuation during follow-up.
Results:67,236 patients (BP-I=50,728; SCZ=4,388; MDD=12,120) were included.The mean follow-up was 4.7(4.1) months.At baseline, 13.2% used sleep medication. MDD cohort had the highest sleep medication use(15.0%), followed by BP-I(13.1%) and SCZ(9.4%).Among those using sleep medication at baseline, overall discontinuation rate during follow-up was 50.2 per 100 person-years (BP-I=51.0;SCZ=45.7;MDD=48.2).During follow-up, the initiation rate for sleep medication among patients not previously using sleep medication was 10.7 per 100 person-years (BP-I=11.3;SCZ=8.1;MDD=9.2).Among patients who began using sleep medication during follow-up, the overall discontinuation rate was 124.2 per 100 person-years (BP-I=119.5;SCZ=128.3;MDD=152.6).The sleep medication use was numerically lower during follow-up(11.0%) and consistent across all indications (BP=11.2%;SCZ=7.8%;MDD=11.7%).
Conclusions:This real-world, claims-based study in patients with BP-I, SCZ, or MDD found lower sleep medication use after cariprazine initiation.
Short Description: This real-world, claims-based analysis of sleep medication treatment patterns in patients with bipolar I disorder, schizophrenia, or major depressive disorder, showed that the prevalence of sleep medication use was lower after versus before cariprazine treatment. The sleep medication discontinuation rate per 100 person-years was higher than the initiation rate per 100 person-years after versus before cariprazine treatment.
Name of Sponsoring Organization(s): AbbVie, Inc.
